Human leucocyte interferon-alpha in the treatment of chronic hepatitis C.
Dig Liver Dis
; 33(4): 347-52, 2001 May.
Article
en En
| MEDLINE
| ID: mdl-11432514
ABSTRACT
AIM:
To assess the efficacy of different schedules of human leucocyte interferon alpha in chronic hepatitis C. PATIENTS ANDMETHODS:
A total of 213 naive patients with chronic hepatitis C were treated with 4 different schedules of human leucocyte interferon alpha. Sustained response was defined as persistently normal alanine amino transferase values with negative serum hepatitis C virus-RNA up to 12 months after therapy withdrawal.RESULTS:
Rates of sustained response were 16% with 3 MU tiw for 6 months, 33% with 6 MU tiw for 5 months after a priming dose of 9 MU tiw for a month, 32% with 3 MU tiw for 12 months and 20% with 3 MU daily for 6 months. The major factors affecting the response rate were age and the hepatitis C virus genotype, as a sustained response was significantly higher in patients under 45 years and infected by hepatitis C virus types other than hepatitis C virus-1. Treatment was well tolerated and side-effects and drop-out events were similar to those described with other types of alpha-interferons.CONCLUSIONS:
Human leucocyte interferon alpha appears to be equivalent to recombinant interferon-alpha in the treatment of chronic hepatitis C.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Interferón-alfa
/
Hepatitis C Crónica
Límite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Dig Liver Dis
Asunto de la revista:
GASTROENTEROLOGIA
Año:
2001
Tipo del documento:
Article
País de afiliación:
Italia